Drug intelligence / Profile preview

methylprednisolone + mizoribine + prednisolone

Development stage: Unknown
Lead developer: Japanese Study Group of Renal Disease in Children
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of methylprednisolone, mizoribine, and prednisolone used primarily for autoimmune disorders. Methylprednisolone and prednisolone are corticosteroids that reduce inflammation and suppress immune responses, while mizoribine is an immunosuppressive agent that may enhance the effects of corticosteroids. This combination has been studied for conditions including systemic lupus erythematosus (SLE), IgA nephropathy, and nephrotic syndrome.

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on methylprednisolone + mizoribine + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylprednisolone + mizoribine + prednisolone.

Explore the full profile